<unk>  is a Janus kinase (JAK) inhibitor that is FDA approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include upper respiratory tract infections, nausea, herpes simplex, and herpes zoster.
Baricitinib
Erdafitinib
Gilteritinib
Brigatinib
Dacomitinib
Ceritinib
Fostamatinib
Neratinib